Literature DB >> 27956145

Recent advances in preclinical model systems for papillomaviruses.

Neil D Christensen1, Lynn R Budgeon2, Nancy M Cladel2, Jiafen Hu2.   

Abstract

Preclinical model systems to study multiple features of the papillomavirus life cycle have greatly aided our understanding of Human Papillomavirus (HPV) biology, disease progression and treatments. The challenge to studying HPV in hosts is that HPV along with most PVs are both species and tissue restricted. Thus, fundamental properties of HPV viral proteins can be assessed in specialized cell culture systems but host responses that involve innate immunity and host restriction factors requires preclinical surrogate models. Fortunately, there are several well-characterized and new animal models of papillomavirus infections that are available to the PV research community. Old models that continue to have value include canine, bovine and rabbit PV models and new rodent models are in place to better assess host-virus interactions. Questions arise as to the strengths and weaknesses of animal PV models for HPV disease and how accurately these preclinical models predict malignant progression, vaccine efficacy and therapeutic control of HPV-associated disease. In this review, we examine current preclinical models and highlight the strengths and weaknesses of the various models as well as provide an update on new opportunities to study the numerous unknowns that persist in the HPV research field.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Animal papillomavirus models; BPV; CPV; CRPV; Codon-modified viral genes; Innate immune responses to PV infections; MmuPV1; Vaccine and immunotherapeutics for PV infections; in vivo PV viral function

Mesh:

Substances:

Year:  2016        PMID: 27956145      PMCID: PMC5361623          DOI: 10.1016/j.virusres.2016.12.004

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  152 in total

1.  Cloning and characterization of a papillomavirus associated with papillomas and carcinomas in the European harvest mouse (Micromys minutus).

Authors:  M K O'Banion; M E Reichmann; J P Sundberg
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

2.  Conserved features in papillomavirus and polyomavirus capsids.

Authors:  D M Belnap; N H Olson; N M Cladel; W W Newcomb; J C Brown; J W Kreider; N D Christensen; T S Baker
Journal:  J Mol Biol       Date:  1996-06-07       Impact factor: 5.469

Review 3.  Reprint of: cancer "causation" by infections--individual contributions and synergistic networks.

Authors:  Harald Zur Hausen; Ethel-Michele de Villiers
Journal:  Semin Oncol       Date:  2015-02-24       Impact factor: 4.929

4.  Protective cell-mediated immunity by DNA vaccination against Papillomavirus L1 capsid protein in the Cottontail Rabbit Papillomavirus model.

Authors:  Jiafen Hu; Nancy M Cladel; Lynn R Budgeon; Cynthia A Reed; Martin D Pickel; Neil D Christensen
Journal:  Viral Immunol       Date:  2006       Impact factor: 2.257

5.  Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles.

Authors:  Andres F Mejia; Timothy D Culp; Nancy M Cladel; Karla K Balogh; Lynn R Budgeon; Christopher B Buck; Neil D Christensen
Journal:  J Virol       Date:  2006-09-27       Impact factor: 5.103

6.  A novel rodent papillomavirus isolated from anogenital lesions in its natural host.

Authors:  Julia Nafz; Kai Schäfer; Su Feng Chen; Ignacio G Bravo; Myriam Ibberson; Ingo Nindl; Eggert Stockfleth; Frank Rösl
Journal:  Virology       Date:  2008-01-29       Impact factor: 3.616

7.  Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus.

Authors:  N D Christensen; C A Reed; N M Cladel; R Han; J W Kreider
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

8.  Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.

Authors:  Mathieu Boxus; Michel Fochesato; Agnès Miseur; Emmanuel Mertens; Najoua Dendouga; Sarah Brendle; Karla K Balogh; Neil D Christensen; Sandra L Giannini
Journal:  J Virol       Date:  2016-06-24       Impact factor: 5.103

9.  A novel pre-clinical murine model to study the life cycle and progression of cervical and anal papillomavirus infections.

Authors:  Nancy M Cladel; Lynn R Budgeon; Karla K Balogh; Timothy K Cooper; Jiafen Hu; Neil D Christensen
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

10.  Immune status, strain background, and anatomic site of inoculation affect mouse papillomavirus (MmuPV1) induction of exophytic papillomas or endophytic trichoblastomas.

Authors:  John P Sundberg; Timothy M Stearns; Joongho Joh; Mary Proctor; Arvind Ingle; Kathleen A Silva; Soheil S Dadras; A Bennett Jenson; Shin-je Ghim
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240

View more
  20 in total

Review 1.  The microbiome and gynaecological cancer development, prevention and therapy.

Authors:  Paweł Łaniewski; Zehra Esra Ilhan; Melissa M Herbst-Kralovetz
Journal:  Nat Rev Urol       Date:  2020-02-18       Impact factor: 14.432

2.  Development of an in vivo infection model to study Mouse papillomavirus-1 (MmuPV1).

Authors:  Aayushi Uberoi; Satoshi Yoshida; Paul F Lambert
Journal:  J Virol Methods       Date:  2017-12-15       Impact factor: 2.014

Review 3.  The rabbit papillomavirus model: a valuable tool to study viral-host interactions.

Authors:  Nancy M Cladel; Xuwen Peng; Neil Christensen; Jiafen Hu
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-05-27       Impact factor: 6.237

4.  Passive Immunization with a Single Monoclonal Neutralizing Antibody Protects against Cutaneous and Mucosal Mouse Papillomavirus Infections.

Authors:  Sarah A Brendle; Jingwei Li; Nancy M Cladel; Karla K Balogh; Jennifer Booth; Debra A Shearer; Vonn Walter; Song Lu; Neil D Christensen; Danielle Covington; Jake DeBroff; Janice Milici; Yusheng Zhu; Raphael Viscidi; Jiafen Hu
Journal:  J Virol       Date:  2022-08-03       Impact factor: 6.549

5.  Insights into the Role of Innate Immunity in Cervicovaginal Papillomavirus Infection from Studies Using Gene-Deficient Mice.

Authors:  Carolina Scagnolari; Fabiana Cannella; Alessandra Pierangeli; Rebecca Mellinger Pilgrim; Guido Antonelli; Dayana Rowley; Margaret Wong; Simon Best; Deyin Xing; Richard B S Roden; Raphael Viscidi
Journal:  J Virol       Date:  2020-06-01       Impact factor: 5.103

6.  Mouse papillomavirus infection persists in mucosal tissues of an immunocompetent mouse strain and progresses to cancer.

Authors:  Nancy M Cladel; Lynn R Budgeon; Karla K Balogh; Timothy K Cooper; Sarah A Brendle; Neil D Christensen; Todd D Schell; Jiafen Hu
Journal:  Sci Rep       Date:  2017-12-05       Impact factor: 4.379

Review 7.  Rodent Papillomaviruses.

Authors:  Aayushi Uberoi; Paul F Lambert
Journal:  Viruses       Date:  2017-11-27       Impact factor: 5.048

Review 8.  Mus musculus Papillomavirus 1: a New Frontier in Animal Models of Papillomavirus Pathogenesis.

Authors:  Megan E Spurgeon; Paul F Lambert
Journal:  J Virol       Date:  2020-04-16       Impact factor: 5.103

Review 9.  Cutaneous Papillomaviruses and Non-melanoma Skin Cancer: Causal Agents or Innocent Bystanders?

Authors:  Daniel Hasche; Sabrina E Vinzón; Frank Rösl
Journal:  Front Microbiol       Date:  2018-05-02       Impact factor: 5.640

Review 10.  The Mouse Papillomavirus Infection Model.

Authors:  Jiafen Hu; Nancy M Cladel; Lynn R Budgeon; Karla K Balogh; Neil D Christensen
Journal:  Viruses       Date:  2017-08-30       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.